Table 1.

Demographic and clinical profile of patients

	Diabetes (n = 166)	No Diabetes (n = 189)	p value
Age (mean ± SD)	66.42 ± 12.67	66.03 ± 15.46	0.797
Female gender n (%)	80 (48)	101 (53)	0.340
Ethnicity n (%)			0.515
African-American	118 (71)	134 (71)
Caucasian	10 (6)	17 (9)
Hispanic	21 (13)	17 (9)
Other	17 (10)	21 (11)
Comorbidities
BMI (mean ± SD)	31.09 ± 8.53	28.53 ± 9.43	0.009
COPD	22 (13)	23 (12)	0.873
Asthma	11 (7)	16 (9)	0.553
Heart failure	40 (24)	20 (11)	0.001
Atrial fibrillation	15 (9)	24 (13)	0.310
Liver cirrhosis	5 (3)	5 (3)	1.000
Chronic kidney disease	42 (25)	23 (12)	0.002
End-stage renal disease on dialysis	27 (16)	14 (7)	0.012
Coronary artery disease	45 (27)	32 (17)	0.028
Hypertension	151 (91)	121 (64)	< 0.0001
HIV	3 (2)	4 (2)	1.000
Clinical and laboratory parameters (mean ± SD)
FiO2% requirement on admission	28 (21–44)	27 (21–40)	0.324
Serum ferritin on admission (ng/mL)	917 (414–1922)	802 (262–1721)	0.187
Peak ferritin (ng/mL)	1375 (594–3605)	1128 (354–2940)	0.074
D-dimer on admission (ng/mL)	2035 (1062–3490)	1605 (820–3095)	0.187
Peak D-dimer (ng/mL)	3710 (1633–8375)	2940 (1315–7923)	0.302
CRP on admission (mg/L)	143 (65–230)	125 (50–192)	0.091
Peak CRP (mg/L)	184 (111–258)	142 (65–229)	0.012
Procalcitonin (ng/mL)	0.28 (0.10–1.13)	0.18 (0.08–0.68)	0.080
Peak procalcitonin (ng/mL)	0.46 (0.11–2.79)	0.28 (0.10–1.19)	0.065
LDH on admission (IU/L)	422 (310–573)	397 (257–537)	0.146
Peak LDH (IU/L)	560 (384–758)	499 (324–655)	0.017
COVID-19 treatment
Hydroxychloroquine	100 (60)	116 (61)	0.828
Steroids	58 (35)	45 (24)	0.026
Tocilizumab	21 (13)	22 (12)	0.871
Clinical outcomes
Median days of hospitalization	7 (4–14)	7 (4–12)	0.831
Inpatient death	45 (27)	35 (19)	0.053
Need for RRT/HD	35 (21)	21 (11)	0.013
Need for vasopressors	47 (28)	34 (18)	0.023
Need for intubation	48 (29)	41 (22)	0.141